Biologic and synthetic skin substitutes

Series
Dermatology
Status
Ongoing
Date
Number of report
084

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of biologic and synthetic skin substitutes in European countries.

The following clinical indications will be considered:

  • burns;
  • chronic wounds (hypertrophic scar).

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of biologic and synthetic skin substitutes include:

  • Allergan (AlloDerm)
  • Anika Therapeutics (HYALOMATRIX)
  • Avita Medical (ReCell)
  • Eurosurgical (Pelnac)
  • Hans Biomed (SureDerm)
  • Integra LifeSciences (Dermal Regeneration Template)
  • MedSkin Solutions (MatriDerm)
  • MiMedx Group (AmnioFix, EpiFix, EpiBurn, AmnioCord, AmnioFill)
  • Modex Therapeutiques (EpiDex)
  • Olympus Terumo Biomaterials (Terudermis)
  • Organogenesis (Dermagraft, NuShield, Affinity, Apligraf)
  • Ortec International (OrCel)
  • Osiris Therapeutics (Grafix, Grafix PL prime)
  • Promethean LifeSciences (GammaGraft)
  • Regenicin (PermaDerm)
  • Smith & Nephew (Biobrane, Oasis, Oasis Ultra)
  • Stryker (DermACELL)
  • Vericel Corporation (Epicel)
  • Wright Medical (GRAFTJACKET)

Table of content is not available at the moment. Report is still ongoing.

20

Sep 2019

The report presents a summary of the reimbursement situation for use of biologic and synthetic skin substitutes in Europe. The following clinical indications are considered: burns; chronic wounds (hypertrophic scar). The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more

20

Sep 2019

The report presents a summary of the reimbursement situation for treatment of burns in Europe. The following types of treatment for burns of are considered: debridement of burn skin; dressing of burnt skin (including vacuum assisted closure device); placement of split-thickness skin autograft. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Read more
(we accept only company emails)